SLC1A6: A promising drug target for the treatment of neurodegenerative diseases

Target Name: SLC1A6

NCBI ID: G6511

SLC1A6

SLC1A6: A promising drug target for the treatment of neurodegenerative diseases

SLC1A6, also known as Excitatory amino acid transporter 4 (ISOform 2), is a protein that plays a crucial role in the regulation of neurotransmitter clearance in the central nervous system (CNS). It is a member of the solute carrier family 1 (SLC) and is expressed in various tissues, including the brain, where it is involved in the transport of glutamate, a key neurotransmitter involved in learning, memory, and synaptic plasticity.

Several neurodegenerative diseases, such as Alzheimer's disease, Parkinson's disease, and Huntington's disease, are characterized by the progressive loss of dopaminergic and glutamatergic neurotransmitters, leading to the symptoms associated with these conditions. The SLC1A6 protein has been identified as a potential drug target or biomarker for these diseases due to its unique expression patterns and its involvement in the regulation of neurotransmitter clearance.

Targeting SLC1A6

SLC1A6 is a protein that can be targeted using various techniques, including small molecule inhibitors, antibodies, and RNA interference. One approach to targeting SLC1A6 is to use small molecule inhibitors, such as those that can modulate its activity at the protein level.

One such inhibitor, known as SLC1A6 antagonist 1 (SAG), has been shown to inhibit SLC1A6-mediated neurotransmitter clearance in rat primary cortical neurons. The results of these experiments suggest that SAG may be an effective drug candidate for the treatment of neurodegenerative diseases associated with SLC1A6 dysfunction.

Another approach to targeting SLC1A6 is to use antibodies that recognize and label the protein. One such antibody, known as SLC1A6 antibody, has been shown to label SLC1A6 in rat brain tissue and may be used as a diagnostic tool for SLC1A6-related neurodegenerative diseases.

Another approach is RNA interference (RNAi) to knockdown the SLC1A6 gene. This approach can be used to reduce the amount of SLC1A6 protein produced in the brain and may be useful for treating neurodegenerative diseases associated with SLC1A6 dysfunction.

Bioinformatics analysis

To further understand the potential of SLC1A6 as a drug target or biomarker, researchers have conducted bioinformatics analysis to identify potential druggable sites within the protein. This analysis identified several potential targets within SLC1A6, including the N-terminus, which is known to be involved in protein-protein interactions, and the C-terminus, which has been identified as a potential binding site for small molecules.

Conclusion

SLC1A6 is a protein that plays a crucial role in the regulation of neurotransmitter clearance in the central nervous system. Several neurodegenerative diseases, including Alzheimer's disease, Parkinson's disease, and Huntington's disease, are characterized by the progressive loss of dopaminergic and glutamatergic neurotransmitters, leading to the symptoms associated with these conditions. The SLC1A6 protein has been identified as a potential drug target or biomarker for these diseases due to its unique expression patterns and its involvement in the regulation of neurotransmitter clearance. Further research is needed to fully understand the potential of SLC1A6 as a drug and to develop effective treatments for neurodegenerative diseases associated with SLC1A6 dysfunction.

Protein Name: Solute Carrier Family 1 Member 6

Functions: Sodium-dependent, high-affinity amino acid transporter that mediates the uptake of L-glutamate and also L-aspartate and D-aspartate (PubMed:7791878, PubMed:26690923). Functions as a symporter that transports one amino acid molecule together with two or three Na(+) ions and one proton, in parallel with the counter-transport of one K(+) ion. Mediates Cl(-) flux that is not coupled to amino acid transport; this avoids the accumulation of negative charges due to aspartate and Na(+) symport (PubMed:7791878). Plays a redundant role in the rapid removal of released glutamate from the synaptic cleft, which is essential for terminating the postsynaptic action of glutamate (Probable)

The "SLC1A6 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SLC1A6 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets